Related Experiment Video
Updated: May 22, 2026
12:13
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Prostate cancer with neuroendocrine differentiation--case report.
1Center of Urology and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania. gabrielgluck@yahoo.com
Journal of Medicine and Life
|May 11, 2012
Summary
Neuroendocrine differentiation in prostate cancer is often undiagnosed and resistant to standard treatments. Early detection through comprehensive follow-up is crucial for better patient outcomes.
Area of Science:
- Oncology
- Pathology
- Urology
Background:
- Prostate adenocarcinoma constitutes 95% of prostate cancers.
- Neuroendocrine cells are present in 10-100% of prostate cancer specimens, depending on detection methods.
Observation:
- A patient with adenocarcinoma of the prostate developed neuroendocrine differentiation.
- This differentiation was identified via immunohistochemistry, showing positivity for Cromogranin A and synaptophysin.
Findings:
- Neuroendocrine prostate cancer exhibits resistance to radiation therapy and chemotherapy.
- The patient progressed to metastatic disease and died of liver failure.
Implications:
- Routine screening for neuroendocrine differentiation is recommended in prostate cancer patients.
- Early detection can guide treatment strategies for this aggressive phenotype.
